Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Therapy Trends KOL Insight: Multiple Sclerosis [2018]

Product Code:
596201086
Publication Date:
November 2018
Format:
PDF + PPTX
Price:
$8,495

How is Ocrevus reshaping the MS treatment landscape?

Oral disease modifying therapies have changed the way MS is treated, but what does the future hold for these agents? Key opinion leaders (KOLs) discuss how these first-line therapies are currently being used and what future threats lie ahead. Has Ocrevus’ approval in relapsing and progressive forms of the disease had an impact on the way KOLs treat the disease? And how is Mavenclad being prescribed in Europe? Other disease modifying therapies are in late-stage development but which segment of the market can they expect to capture?

Learn how KOLs see the market evolving, and how they expect developers to differentiate their marketed and pipeline therapies in Therapy Trends KOL Insight: Multiple Sclerosis. Twelve of the world’s most prominent KOLs provide their candid insights on nine marketed products and eight Phase III pipeline programmes.

Download sample pages

Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!

Top takeaways

  • How is Ocrevus currently being prescribed and what lies ahead? With approval in RRMS and PPMS, how is this drug currently used and will there be any threats to its market share in the future?
  • How important is siponimod’s future approval for SPMS? How clinically attractive is siponimod and will it revolutionise SPMS therapy?
  • What factors will be crucial in determining the future success of ozanimod? Do KOLs think this agent has any advantages over Gilenya?
  • Is ofatumumab considered a real threat to Ocrevus? Do KOLs see any potential advantages to ofatumumab over Ocrevus, other than its subcutaneous route of administration? 
  • What impact is Mavenclad having in Europe? How are European KOLs prescribing this product, and is it taking market share from any other therapy?
  • What issues will need to be addressed in order for Qizenday (pharmaceutical-grade biotin) to be a success? KOLs discuss the ongoing late-stage study, but what specific hurdles will this drug need to overcome to have a successful launch?
  • Will the oral disease-modifying therapies face any threats in the future? Find out whether KOLs think these agents’ market share will increase, decrease or stay stable in the near future?
  • How has interferon beta prescribing changed? What are the reasons for a shift in interferon beta prescribing and how do KOLs envision their use in the future?
  • Will Copaxone remain an important treatment option in the future? Find out KOLs’ thoughts on how this drug will be prescribed in the future and what impact a once-monthly depot formulation is likely to have.
Request sample pages

Back to the top

Quotes

“I would say the key event that could really change the field are approaches that go look at treating patients earlier and earlier; even going as far as preventing MS — so completely different sort of studies.”
EU Key Opinion Leader

“Maybe five years from now we will be using combination therapy because this is very badly needed. Combination therapy will be one of these high efficacy drugs combined maybe with biotin; maybe ocrelizumab or ofatumumab with biotin.”
EU Key Opinion Leader

Sample of therapies covered

Marketed Therapies

  • Interferon beta products (Biogen/Merck Serono/EMD Serono/Bayer/Novartis)
  • Copaxone (glatiramer acetate; Teva)
  • Tecfidera (dimethyl fumarate; Biogen)
  • Aubagio (teriflunomide; Sanofi/Genzyme)
  • Gilenya (fingolimod; Novartis)
  • Tysabri (natalizumab; Biogen)
  • Lemtrada (alemtuzumab; Sanofi)
  • Ocrevus (ocrelizumab; Roche/Biogen)
  • Mavenclad (cladribine; Merck Group)

Pipeline Therapies

  • siponimod (BAF 312; Novartis)
  • ozanimod (RPC 1063; Celgene)
  • ponesimod (ACT 128800; Actelion)
  • ofatumumab (Novartis/Genmab)
  • ublituximab (TG 1101; TG Therapeutics)
  • Qizenday (biotin, MD1003; MedDay/Medical Need)
  • diroximel fumarate (ALKS 8700; Alkermes/Biogen)
  • masitinib (AB Science)

KOLs interviewed

KOLs from North America

  • Prof Mark Freedman, MD, Professor of Medicine in the field of neurology at the University of Ottawa and Director of the Multiple Sclerosis Research Unit at the Ottawa Hospital, General Campus, Ottawa, Ontario, Canada
  • Prof David Hafler, MD, William S. and Lois Stiles Edgerly Professor and Chairman of Neurology, Yale School of Medicine and the Neurologist-in-Chief of the Yale-New Haven Hospital, New Haven, CT, USA
  • Prof Aaron Miller, MD, Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis and Professor & Vice-Chair for Education, Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Prof Rob Naismith, MD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, MO, USA
  • Prof Shiv Saidha, MD, MBBCh, Associate Professor of Neurology at Johns Hopkins Medicine, Baltimore, MD, USA
  • Prof Bianca Weinstock-Guttman, MD, Professor of Neurology and Director of the Jacobs Multiple Sclerosis Center for Treatment and Research, University at Buffalo (SUNY), Buffalo, NY, USA

KOLs from Europe

  • Prof Óscar Fernández, MD, Professor, Medical Neurologist and Senior Investigator at the Hospital Universitario Virgen de la Victoria, Málaga, Spain
  • Prof Antonio Uccelli, MD, Professor of Neurology at the University of Genoa, and Scientific Director of Ospedale Policlinico San Martino, Sistema Sanitario Regione Liguria, Istituto di Ricovero e Cura a Carattere Scientifico per l’Oncologia, Genoa, Italy
  • Prof Celia Oreja-Guevara, MD, Chair of Clinical Research, Multiple Sclerosis Unit, Department of Neurology, IdISSC, University Hospital San Carlos, Madrid, Spain
  • Prof Gilles Defer, MD, Head of the Department of Neurology at University Hospital of Caen, France
  • Prof Cris Constantinescu, MD, Professor of Neurology, Faculty of Medicine & Health Sciences, University of Nottingham, UK
  • Anonymous, German KOL, Professor of Neurology at a leading German university hospital

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.



customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved